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Abstract 
Parkinson’s disease (PD) is a progressive, neurodegenerative disease that presents with 
significant motor symptoms, for which there is no diagnostic test. We have serendipitously 
identified a hyperosmic individual, a ‘Super Smeller’ that can detect PD by odor alone, and 
our early pilot studies have indicated that the odor was present in the sebum from the skin of 
PD subjects. Here, we have employed an unbiased approach to investigate the volatile 
metabolites of sebum samples obtained non-invasively from the upper back of 64 
participants in total (21 controls and 43 PD subjects). Our results, validated by an 
independent cohort, identified a distinct volatiles-associated signature of PD, including 
altered levels of perillic aldehyde and eicosane, the smell of which was then described as 
being highly similar to the scent of PD by our ‘Super Smeller’. 
 
Background 
Physicians in ancient times, including Hippocrates, Galenus, and Avicenna, used odor as a 
diagnostic tool. Although the olfactory skills of physicians are not routinely used in modern 
medicine, it is well documented that a number of conditions, predominantly metabolic and 
infectious diseases, are associated with a unique odor1, but there is scant evidence for odors as 
symptoms of neurodegenerative disorders. To the best of our knowledge this is the first study 
that demonstrates the use of sebum as biofluid to screen for Parkinson’s disease. There have 
been a small number of metabolomics studies of Parkinson’s disease using various biofluids such 
as blood, faeces, saliva, urine, cerebrospinal fluid as well as insect and mouse models of 
Parkinson’s as described in this recent review by Shao and Le2, there is no mention of a 'PD odor'. 
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Joy Milne, a Super Smeller whose husband Les was diagnosed with PD in 1986, has demonstrated 
a unique ability to detect PD by odor3. Joy has an extremely sensitive sense of smell, and this 
enables her to detect and discriminate odors not normally detected by those of an average 
olfactory ability. Preliminary tests with t-shirts and medical gauze indicated the odor was present 
in areas of high sebum production, namely the upper back and forehead, and not present in 
armpits3. Sebum is a waxy, lipid-rich biofluid excreted by the sebaceous glands in the skin, over-
production of which known as seborrhea, is a known non-motor symptom of PD4-5. Parkinson’s 
skin has recently been shown to contain phosphorylated α-synuclein, a molecular hallmark of 
PD6-7. Identification and quantification of the compounds that are associated with this distinctive 
PD odor could enable rapid, early screening of PD as well as provide insights into molecular 
changes that occur as the disease progresses and enable stratification of the disease in future. 
 
Volatile organic compounds (VOCs) are often associated with characteristic odors, although some 
volatiles may also be odorless. The term ‘volatilome’ describes the entirety of the volatile organic 
and inorganic compounds that may originate from any organism, or object, which may be 
analytically characterized. For any given sample under ambient conditions in a confined 
environment, collecting, identifying, and measuring molecules in its headspace will then define its 
volatilome. Such measurements can be performed with thermal desorption gas chromatography 
mass spectrometry (TD-GC-MS), where a sample is placed in a closed vessel. The sample is then 
heated to encourage the production of volatiles and the headspace is captured for analysis by GC-
MS. Investigation of volatile metabolites using mass spectrometry has proven to be extremely 
useful in clinical studies8-11  as well as in the analysis of the consistency and provenance of edible 
items12-14. Recently, TD-GC-MS has been used as a volatilome analysis platform for the detection 
of compounds from bacteria implicated in ventilator associated pneumonia10, for differentiation 
between odors due to human and animal decomposition15, as well as aerosol detection of the 
fumes from e-cigarettes16. This versatility of TD-GC-MS for samples from many sources renders it 
highly suitable for use in identifying the metabolites that give rise to the distinct scent of PD. We 
have established a workflow that starts in clinics with the collections of sebum samples from the 
upper backs of PD patients along with matched control subjects and progresses to the discovery 
of disease specific volatile metabolites, the odor of which is confirmed by our Super Smeller. 
(Figure 1, Supplementary information and Table S1A). 
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In the current study, VOCs from the sample headspace were measured in two cohorts: a 
‘discovery’ cohort (n=30) and a ‘validation’ cohort (n=31), to validate discovered biomarkers17 (for 
demographics of each cohort see Table S1B and S5). A third cohort consisting of three drug-naïve 
PD participants was used for mass spectrometry analysis in conjunction with a human Super 
Smeller via an odor port (Figure 1). This proof of principal study provides the first description of 
the skin volatilome in Parkinson’s disease compared to control subjects. 
 
Study Participants 
The participants for this study were part of a nationwide recruitment process taking place at 25 
different NHS clinics. The participants for this study were selected at random from these sites. 
The study was performed in three stages. The first two stages (discovery and validation) consisted 
of 61 samples (a mixture of control, PD participants on medication and drug naïve PD subjects as 
shown in Table S1B). The first cohort was used for volatilome discovery, and the second cohort 
was used to validate the significant features discovered in first cohort. A third cohort consisting of 
three drug naïve PD participants was used for smell analysis from the Super Smeller. Ethical 
approval for this project (IRAS project ID 191917) was obtained by the NHS Health Research 
Authority (REC reference: 15/SW/0354). The metadata analysis for these participants is reported 
in Table S1B. The study design was as outlined in Figure1. 
 
Sample collection 
The sampling involved each subject being swabbed on the upper back with a medical gauze. The 
gauze with sebum sample from participant’s upper back was sealed in background-inert plastic 
bags and transported to the central facility at the University of Manchester, where they were 
stored at -80 ⁰C until the date of analysis. 
 
 
Analytical Method: TD-GC-MS analysis 
 
Description of the technique 
A Dynamic Headspace (DHS) GC-MS method was developed for the analysis of gauze swabs 
which contained sampled participant sebum. DHS is a sample preparation capability for 
subsequent GC application using the GERSTEL MultiPurpose Sampler (MPS). DHS extracts and 
concentrates VOCs from liquid or solid samples. The sample is incubated while the headspace is 
purged with a controlled flow of inert gas through an adsorbent tube. Once extraction and pre-
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concentration are completed, the adsorbent tube is automatically desorbed using the GERSTEL 
Thermal Desorption Unit (TDU). Analytes are then cryo-focused on the GERSTEL Cool Injection 
System (CIS) Programmed Temperature Vaporizer (PTV) injector before being transferred to the 
GC for analysis. 
In order to correlate the PD molecular signature to the PD smell, the same setup was used in 
combination with the GERSTEL Olfactory Detection Port (ODP). The ODP allows detection of 
odorous compounds as they elute from the GC by smell. In fact, the gas flow is split as it leaves 
the column between the detector of choice (in our case MS) and the ODP to allow simultaneous 
detection on the two analytical tools.  The additional smell profile information can then be 
acquired as an olfactogram. Voice recognition software and intensity registration allow direct 
annotation of the chromatogram.  
 
Method details 
Gauze swabs were transferred into 20 mL headspace vials and then analyzed by DHS-TD-GC-MS. 
For the DHS preconcentration step, samples were incubated for 5 min at 60 ⁰C before proceeding 
with the trapping step. Trapping was performed by purging 500 mL of the sample headspace at 
50 mL.min-1 through a Tenax® TA adsorbent tube kept at 40 ⁰C (GERSTEL, Germany). Nitrogen 
was used as purge gas. To release the analytes, the adsorbent trap was desorbed in the TDU in 
splitless mode. The TDU was kept at 30 ⁰C for 1 min then ramped at 12 ⁰C.sec-1 to 250 ⁰C and held 
for 5 min. Desorbed analytes were cryofocused in the CIS injector. The CIS was operated in 
solvent vent mode, using a vent flow of 80 mL.min-1 and applying a split ratio of 10. The initial 
temperature was kept at 10 ⁰C for 2 min, then ramped at 12 ⁰C.s-1 to 250 ⁰C and held for 10 min. 
The GC analysis was performed on an Agilent GC 7890B coupled to an Agilent MSD 5977B 
equipped with high efficiency source (HES) operating in EI mode. Separation was achieved on an 
Agilent HP-5MS Ultra inert 30 m x 0.25 mm x 0.25 µm column. The column flow was kept at 1 
mL.min-1. The oven ramp was programmed as following: 40 °C held for 5 min, 10 °C.min-1 to 170 
°C, 8 °C.min-1 to 250 °C, 10 °C.min-1 to 260 °C held for 2 min for a total run time of 31 min. The 
transfer line to the MS was kept at 300 °C. The HES source was kept at 230 °C and the Quadrupole 
at 150 °C. The MSD was operated in scan mode for mass range between 30 and 800 m/z. For the 
olfactometry approach, the chromatographic flow was split between the mass spectrometer and 
the GERSTEL Olfactory Detection Port (ODP3) using Agilent Technologies Capillary Flow 
Technology (three-way splitter plate equipped with make-up gas). The ODP3 transfer line was 
kept at 100 °C and humidity of the nose cone was maintained constant. 
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Data pre-processing and deconvolution  
TD-GC-MS data were converted to open source mzXML format using ProteoWizard. Each cohort 
data were deconvolved separately using eRah package for  R18. Upon deconvolution, in discovery 
cohort 207 features and in validation cohort 210 features were assigned to detected peaks. The 
deconvolved analytes were assigned putative identifications by matching fragment spectra with 
compound spectra present in Golm database, NIST library and Fiehn GCMS library. In discovery 
cohort 163 features were assigned an identification and in validation cohort 156 features were 
assigned an identification. The resulting matrices for each cohort consisted of variables and their 
respective area under the peak for each sample. All data were normalised for age and total ion 
count to account for confounding variables (Table S1B).  
 
Statistical analyses 
The discovery cohort data included a global analysis of all the detected compounds. PLS-DA 
modelling was carried out using all the measured features. We have not included PCA results 
because using this unsupervised clustering method, we were unable to see any clustering of data. 
We attribute this to the complex nature of metabolomics data especially for volatile metabolites. 
This results in high dimensionality of the data and it is unrealistic to expect that the separation 
between PD and controls to be the most dominating variance in the data and thus results in 
poorer display on PCA/MDS plots. Often supervised modelling is required to train the models to 
find defined differences by overcoming noise.  
 
The data were log-scaled, and Pareto scaled prior to Wilcoxon-Mann-Whitney analysis, PLS-DA 
and the production of ROC curves. The PLS-DA was created and executed using MATLAB 
(2018a)19-20 and the MATLAB functions are freely available from our in-house cluster toolbox 
hosted at https://github.com/biospec. ROC curves were generated using the R package called 
pROC21. The samples from both cohorts were combined, thus increasing sample size and 
providing better statistical power while evaluating the performance of this panel of biomarkers 
(Figure 2C, Figure S1). ROC curves were generated by Monte-Carlo cross validations (MCCV) 
using balanced sub-sampling. In each of the MCCV, two thirds of the samples were used to 
evaluate the feature importance. The top two, three, five, seven and nine important features 
were then used to build classification models, which were validated using the remaining one third 
of the samples. The process was repeated 500 times to calculate the average performance and 
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confidence interval of each model. Classification and feature ranking were performed using a 
PLS-DA algorithm using two latent variables (Figure 2C).  
When performing k-nearest neighbours analysis, k was chosen to be 5 given the small sample 
size, the distance parameter used was Euclidean distance which was used as weights such that 
closer neighbours of a query point have a greater influence than the neighbours further away. 
During random forest analysis of the same data, 10 decision trees were grown, and the growth 
control was achieved by not splitting into subsets smaller than five. SVM model was built using 
LIBSVM, implemented in e1071 package of R22, with a linear kernel. The cost (C) and regression 
loss epsilon () were determined by performing a grid search and were set at C=10 and  was set 
at 0.10.   
 
Results and discussion 
Mass spectrometry data were collected, deconvolved and pre-processed as described in the 
supplementary information. A partial least squares discriminant analysis (PLS-DA) model was 
built using the discovery cohort data (Figure 2). The classification accuracy of this model was 
validated by bootstrapping approach (n=1000). The variables contributing to classification (n=17) 
were selected using variable importance in projections (VIP) scores where VIP > 1. We note at this 
stage that one of the 17 metabolites found is 3,4-dihydroxy mandelic acid, a metabolite of 
norepinephrine in humans. This catechol is also a metabolite of L-dopa, one of the most 
commonly prescribed medication for Parkinson’s. In this study, 3,4-dihydroxy mandelic acid is 
observed in both drug naïve participants and control participants indicating its presence may 
originate from endogenous mandelic acid instead of PD drugs. Norepinephrines including 3,4-
dihydroxy mandelic acid are key molecules in the anabolism of brain neurotransmitters. Changes 
in neurons and neurotransmitters is an extremely well-known characterization of PD23, for 
instance the decrease of dopamines, a precursor to 3,4-dihydroxy mandelic acid is a known 
characterization of PD. It could, therefore, be hypothesized that the presence of endogenous 3,4-
dihydroxy mandelic acid could be indicative of altered levels of neurotransmitters in PD. 
 
The measured volatilome in the validation cohort data (from a different population than the 
discovery cohort) was targeted for the presence or absence of these discovered biomarkers. Out 
of these 17 metabolites, 13 were also found in the validation cohort data, and nine of these had 
retention times that allowed us to confidently assign them as identical (Table S2). These nine 
biomarkers found in both cohorts were selected for further analysis and statistical testing. To 
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evaluate the performance of these biomarkers, we conducted receiver operating characteristic 
(ROC) analyses with data from both the discovery cohort and the validation cohort (Figure S1). 
ROC curves and Wilcoxon-Mann-Whitney tests as well as fold-change calculations on individual 
metabolites shows four out of these nine metabolites had a similar trend in regulation between 
the discovery and validation cohorts and their performance was also similar as measured by AUC 
(Table 1, Figure 3). The results from the combined analysis using both cohorts as a single 
experiment, indicate increased confidence in the data (p-values in Table 1, confidence intervals in 
Figure S1).  
 
We adhered to the Metabolomics Standards Initiative (MSI) guidelines for data analysis and for 
assignment of identity to features of interest17 and all identified features are at MSI level two, 
which means these are putatively annotated compounds (e.g. without chemical reference 
standards, based upon physicochemical properties and/or spectral similarity with 
public/commercial spectral libraries). The compounds perillic aldehyde and eicosane are 
significantly different between PD and control in both the cohorts (p < 0.05): perillic aldehyde was 
observed to be lower in PD samples whereas eicosane was observed at significantly higher levels. 
Although hippuric acid and octadecanal were not significantly different (p > 0.05), the AUC and 
box plots (Figure 3) between the two cohorts were comparable and showed similar trends of 
being increased in PD. Previous studies have reported varying abundances of these compounds in 
other biofluids (Table 2). 
 
Using an odor port attached to the GC-MS instrument, the Super Smeller identified times at 
which any smell was present and also more importantly the times at which a specific ‘musky’ 
smell of PD was detected. Data were presented in the form of an olfactogram, where the 
presence and relative intensity of each smell were recorded at its corresponding chromatographic 
retention time. Olfactogram results obtained from the odor port were overlaid on the respective 
total ion chromatogram from GC-MS (Figure 4A). There was significant overlap between regions 
that contained up-regulated compounds and regions in which a smell similar or identical to that 
of PD scent was present. In the chromatographic trace the region between 19 and 21 min is of 
particular interest (Figure 4B) since the smell associated with the mixture of analytes in that 
window was described as “very strong” and “musky”. This is the same region where three 
compounds viz. hippuric acid, eicosane and octadecanal have been detected in both cohorts and 
all three were found to be up-regulated in PD subjects.  
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In order to validate mass spectrometry led biomarkers and to verify the resultant scent, the 
candidate compounds listed in Table S2 (n=17) were purchased and spiked onto gauze swabs 
(Table S3). An exploratory study with our Super Smeller was performed in which multiple 
mixtures of compounds (n=5) were spiked onto both blank gauze swabs and swabs that contained 
control sebum. Two final dispensed volumes of the mixtures were tested (40 µL and 100 µL) and 
all compounds used were at a single concentration (10 µM). In these blinded tests the Super 
Smeller grouped the samples in order of PD-like odor. She was able to isolate the swabs with a 
sebum background matrix and described them as more familiar to the PD-like smell than without 
control sebum. Further tests utilized control sebum as a background matrix for spiking candidate 
compounds and a range of concentrations was then selected for testing. Mixtures of the 
candidate compounds (n=17) were prepared at a range of concentrations (10 µM, 5 µM, 0.5 µM, 
0.05 µM, 0.005 µM) and presented to the Super Smeller in a second blinded test, she was again 
asked to rank in order of PD-like smell. These results demonstrated she could detect (although 
not systematically order) the whole range of concentrations offered, and a concentration 
between 0.05 µM and 0.5 µM gave her the best response. A validation study consisting of three 
compound mixtures with significance from the MS analysis aimed to distinguish the combination 
that best gave rise to the most PD-like smell. Three mixture combinations were chosen at a single 
concentration (0.5 µM); all candidate compounds (n=17), all compounds identified in both the 
discovery and validation cohorts (n=9) and the panel of compounds expressed in same direction 
and differential between PD and control (n=4). The mixture of 9 compounds was consistently 
described as being most akin to the PD-like odor and was slightly overlapped by description and 
rank with the mixture of 4 compounds. The mixture of 17 compounds was grouped as the same 
'smell' as the other two combinations however were described as significantly weaker. We 
hypothesize this is due to a lower concentration of each compound in the mixture and thus higher 
interference from background solvent smell. The results from these tests are depicted in Figure 
S2 whereby the intensity and correlation to the PD-like smell partitions the groups of samples 
tested. We do not conclude that these chemicals alone constitute the unique smell associated 
with PD, rather we demonstrate that they contribute to it.  
 
From results obtained from three independent sets of data, from different people with one 
underlying factor (i.e. PD) separating them, it was clear that several volatile features were found 
to be significantly different between control and PD participants.  There were no significant 
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differences observed between PD participants on medication and drug naïve PD participants (p > 
0.05 for all measured volatiles), indicating that the majority of the analyzed volatilome and by 
inference sebum, are unlikely to contain drug metabolites associated with PD medication. In 
addition, applying machine learning approaches such as k-nearest neighbours, random forest and 
support vector machines (SVM) did not lead to a classification between drug naïve PD 
participants and PD participants on medication (results in Table S4).  
 
Perillic aldehyde and octadecanal are ordinarily observed as plant metabolites or food additives. It 
can be hypothesised that with increased and altered sebum secretion such lipid-like hydrophobic 
metabolites may be better captured or retained on the sebum-rich skin of PD subjects. Skin 
disorders in Parkinson’s have been observed previously and seborrheic dermatitis (SD) in 
particular has been flagged as a premotor feature of PD23. It has been reported by Arsenijevic and 
coworkers5 that PD patients who suffer from SD have increased Malassezia density on their skin 
and commensurate higher lipase activity required metabolically by yeast. This increased lipase 
activity could correlate with the enhanced production of eicosane, perillic aldehyde and 
octadecanal as highly lipophilic molecules since Malassezia requires specific exogenous lipids for 
growth.  Eicosane is reported as being produced by Streptomyces as an anti-fungal agent24 which 
also supports its increased presence on the skin of PD sufferers. The effects observed in our study 
could also signal altered microbial activity on the skin of PD patients that may affect the skin 
microflora causing changes in the production of metabolites such as hippuric acid25.  These 
potential explanations for the change in odor in PD patients all suggest a change in skin 
microflora and skin physiology that is highly specific to PD. 
 
Conclusion 
In conclusion, our study highlights the potential of comprehensive analysis of sebum from PD 
patients and raises the possibility that individuals can be screened non-invasively based on 
targeted analysis for these volatile biomarkers. We do acknowledge that the current study is 
limited with smaller sample size, but the power of this study is a different validation cohort that 
consisted of completely different participants. This validation cohort was able to verify the 
findings and classification model built using data from our discovery cohort.  A larger study with 
extended olfactory data from human smellers as well as canine smellers in addition to headspace 
analyses is the next step in further characterizing the PD sebum volatilome. This will enable the 
establishment of a panel of volatile biomarkers associated with PD and will open new avenues for 
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stratification as well as facilitate earlier detection of PD and further the understanding of disease 
mechanisms. 
 
Safety statement: No unexpected or unusually high safety hazards were encountered in the 
course of this work. 
 
Supplementary information includes description of sampling methodology, analytical methods 
used and has supplementary figures and tables as well as list of all the PIs from recruitment 
centers that participated in this study. 
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Figure 1: Schematic outline of the workflow described in this study - from sample collection to biomarker discovery. Parkinson's disease patient 
samples and control participant samples were collected from 25 sites across the UK using gauze swabs to sample the sebum from the top back 
region from 64 people. Thermal desorption-gas chromatography-mass spectrometry (TD-GC-MS) analysis was performed alongside olfactory 
analysis results of which were then combined. Statistical analysis was performed on two independent cohorts. Data from discovery cohort 
consisting of 30 participants were used to create a partial least squares-discriminant analysis (PLS-DA) model and differential features found as a 
result were then targeted for presence in a separate validation cohort consisting of 31 participants. The significance of these biomarkers was tested 
using receiver operating characteristic (ROC) analyses and Wilcoxon-Mann-Whitney test. Finally, four features that showed similar statistical 
significance and expression on both cohorts were selected for biological interpretation of data.  
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Figure 2: PLS-DA classification model (A) Classification matrix of PLS-DA model validated using 
5-fold cross validation showing 90% correct prediction of Parkinson’s disease samples (B) PLS-DA 
modelling was further tested using permutation tests (where the output classification was 
randomised; n=26) and results are plotted as a histogram which shows frequency distribution of 
correct classification rate (CCR) which yielded CCRs ranging between 0.4 to 0.9 for permutated 
models. The observed model was significantly better than most of the permuted models (p < 0.1); 
shown by the red arrow. (C) ROC plot generated using combined samples from both cohorts and 
the panel of four metabolites that were common and differential between control and PD. The 
shaded blue area indicates 95% confidence intervals calculated by Monte Carlo Cross Validation 
(MCCV) using balanced sub-sampling with multiple repeats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 3: ROC curves and box plots for analytes of interest: In each panel from top to bottom: ROC curves for both discovery (blue) and validation 
(red) cohort for four analytes common to both experiments. Confidence intervals were computed with 2000 stratified bootstrap replicates and 
diagonal black line represents random guess. Box plots show comparison of means of log scaled peak intensities of these analytes, where black dots 
were outliers. 
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Figure 4: Comparison of GC-MS chromatogram to description of olfactory data described by 
the Super Smeller: GC-MS chromatogram from three drug naïve Parkinson’s subjects and a 
blank gauze. (A) The 10 to 25 min retention time range of the chromatographic analysis in which 
the Super Smeller described various odors associated with different GC-MS peaks. The overlaid 
green shaded area shows the overlap between real time GC-MS analysis and the Super Smeller 
describing a 'strong PD smell' via the odor port.  
(B) A zoom of the green highlighted area from A. This region is of particular interest as 3 out of 4 
identified compounds are found here (Tables 1 and S2); it encompasses the time during which the 
Super Smeller described a musky PD-like scent as being 'very strong' (between the time lines at 
19 and 21 min) for the PD samples and not for the blank. It can be noted that none of these 
compounds are found in blank gauze (bottom chromatogram) within the same retention time 
window as shown by normalized relative peak intensities to the highest peak in each 
chromatogram. The area between black dotted lines highlight the presence of compounds in PD 
samples but complete absence in blank gauze.  
 
 
 
 
 
 
 
Table 1 : Panel of four volatile metabolites that were found to be differential between Parkinson’s 
and control samples, with similar trends observed in expression and AUC curves measured by 
 Page 16 
ROC analyses. Perillic aldehyde and Eicosane were significantly down-regulated and up-regulated 
in PD, respectively (FDR corrected p < 0.05) in both cohorts. 
 
 
Putative 
identification 
Parent 
Mass 
∆RT 
(min) 
FDR corrected p-value 
(Mann-Whitney test) 
Expression 
(PD/Control) 
   Discovery Validation Combined Discovery Validation 
Perillic aldehyde 150.22 0.15 0.0279 0.0403 <0.0001 Down Down 
Hippuric acid 179.17 0.09 0.1908 0.0403 0.1833 Up Up 
Eicosane 282.56 0.03 0.0279 0.0403 0.0013 Up Up 
Octadecanal 170.34 0.12 0.2605 0.0604 0.3040 Up Up 
 
Table 2: Known normal abundances of molecules of interest (listed in table 1) measured using 
mass spectrometry approaches, as reported in literature  
Molecule Biospecimen Abundance Reference 
Eicosane Faeces Not quantified Garner et al26 
 Saliva Not quantified Soini et al27 
 Saliva Not quantified Costello et al28 
Hippuric acid Cerebrospinal 
fluid 
3.0 (0.0-0.5) M Hoffman et al29 
 Urine Not quantified Hanhineva et al30 
 Blood 16.74  11.16 M Duraton et al31 
Octadecanal Faeces Not quantified Dixon et al32 
Perillic aldehyde Saliva Not quantified Costello et al28 
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Synopsis: 
 
Sebum from upper-back, analyzed using mass spectrometer hyphenated to an odour port reveals 
a unique volatilome associated to Parkinson’s disease (PD) smell, useful for diagnosing PD non-
invasively. 
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Supplementary Information 
 
Table S1A Details of the collecting sites in the UK and the lead PI at each site 
 SITE 
NUMBER 
SITE NAME PI 
1 Addenbrookes (Cambridge) Paul Worth 
2 Bournemouth Khaled Amar 
3 Cornwall/Truro Christine Schofield 
4 Lothian - Western General 
Edinburgh 
Gordon Duncan 
5 Edinburgh – Royal Infirmary of 
Edinburgh 
Gordon Duncan 
6 Edinburgh - Primary Care NHS 
Lothian (Seb Derm) 
Richard Weller 
7 Hampshire Sam Arianayagam 
8 Nottingham Gill Sare 
9 Pennine Jason Raw 
10 Salford Monty Silverdale 
11 Salisbury Diran Padiachy 
12 Sheffield Oliver Bandmann 
13 South Tees Neil Archibold 
14 Southern Health Helen Roberts 
15 Luton & Dunstable Anette Schrag 
16 Portsmouth Sean Slaght 
17 Northumbria Richard Walker 
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18 London North West Sophie Molloy 
19 Bath Veronica Lyell 
20 Gateshead Richard Athey 
21 Sunderland Uma Nath 
22 Plymouth Camille Caroll 
23 Newcastle Upon Tyne Hospitals 
NHS Foundation Trust (Newcastle 
University) 
Nicola Pavese 
24 Royal Devon and Exeter NHS 
Foundation Trust 
Robert James 
25 Imperial College Healthcare NHS 
Trust 
Sophie Molloy 
 
 
Table S1B: Participant numbers and metadata per wave.  
Discovery cohort 
 Control 
(n=10) 
Drug Naïve PD (n=10) PD on medication 
(n=10) 
p-value 
Age (years) 64.8 ± 3.06 72.82 ± 8.42 64.67 ± 2.55 0.01* 
BMI 27.10 ± 3.50 26.94 ± 4.08 25.33 ± 3.44 0.64 
Gender (M/F ratio) 0.84 1.20 0.80 0.88 
Alcohol intake (yes/no 
ratio) 
4.5 0.37 2 0.03* 
Smoker 1 0 0 0.39 
Validation cohort 
 Control 
(n=11) 
Drug Naïve PD (n=11) PD on medication 
(n=9) 
p-value 
Age (years) 55.78 ± 18.87 75.40 ± 6.85 68.90 ± 11.76 0.02* 
BMI 28.96 ± 11.01 25.74 ± 3.83 24.98 ± 3.54 1.00 
Gender (M/F ratio) 0.26 1.50 1 0.10 
Alcohol intake (yes/no 
ratio) 
0.8 9 1.5 0.10 
Smoker 0 0 1 0.24 
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Wave 3 (odor port validation, drug naïve PD subjects only, n=3) 
Age (years) 65.66 ± 3.30 
BMI 23.46 ± 1.80 
Gender (M/F ratio) 2 
Alcohol intake (yes/no 
ratio) 
2 
Smoker 0 
 
 * indicates significant difference between controls, drug naïve and PD with medication groups. 
 
Table S2: List of candidate volatiles putatively identified (MSI level 2) and matched across two 
different cohorts. Nine of out 17 metabolites listed were selected for further analysis since they 
had acceptable retention time drift between the two sets of experiments. 
 
 
 
 
 
 
Putative identification Mass 
Retention time 
(min) 
(discovery) 
Retention time 
(min) 
(validation) 
Retention time 
(min) 
difference Comments 
3,4-dihydroxy mandelic acid 184.15 20.87 Not found n/a Not found 
Artemisinic acid 234.34 12.97 12.83 0.14 Included 
Cyclohexasiloxane, dodecamethyl 357.57 16.47 16.06 0.41 Excluded 
Cyclohexylcyclohexane 357.57 15.36 14.71 0.65 Excluded 
Dodecane 170.34 13.20 13.27 -0.07 Included 
Eicosane 282.56 20.65 20.62 0.03 Included 
Gallic acid ethyl ester 198.17 11.40 10.99 0.41 Excluded 
Glutamine 128.09 21.73 21.09 0.64 Excluded 
Hexyl acetate  170.34 11.70 11.53 0.16 Included 
Hippuric acid 179.17 20.61 20.52 0.09 Included 
Neoabietic acid 302.46 21.66 Not found n/a Not found 
Octacosane 394.77 17.49 17.46 0.03 Included 
Octadecanal 170.34 20.87 20.75 0.12 Included 
Octanal 244.38 11.58 11.32 0.26 Included 
Perillic aldehyde 150.22 11.82 11.66 0.15 Included 
Proline 115.13 14.27 13.77 0.50 Excluded 
Tetracosane 338.65 18.17 Not found n/a Not found 
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Table S3: Various standards used to create chemical mixtures that were spiked on gauze 
containing human sebum, were made by dissolving them in appropriate solvents. The table 
shows solvents in which each of these standards were individually created, before forming 
mixtures at various concentrations used for validation of smell by the Super Smeller. 
Standard Solvent 
3,4-dihydroxy mandelic acid Water 
Cyclohexasiloxane, dodecamethyl Methanol 
Cyclohexylcyclohexane Methanol 
Diglycerol Water 
Dodecane Ethanol 
Eicosane Acetone 
Gallic acid ethyl ester Water 
Glutamine Water 
Hexyl acetate MeOH 
Hippuric Acid Water 
Hydroxymyristic acid Dichloromethane 
Octacosane Chloroform 
Octanal Methanol 
Perillic aldehyde Water 
Proline Water 
 
 
Table S4: Classification approaches attempted to distinguish between drug naïve PD participants 
and PD participants on medication did not show a very clear classification between the two 
groups in discovery cohort and validation cohort. K-nearest neighbours, random forest and 
support vector machines (SVM) classification algorithms were used. Using random sampling 
repeated 10 times, 60% data were used for training set and remaining data were used to test the 
model. Area under the curve (AUC) and averaged classification accuracy (ACA) for each model are 
shown.  
 Discovery cohort Validation cohort 
Method AUC ACA AUC ACA 
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Table S5: List of participants’ anonymized ID along with time since they were diagnosed with 
Parkinson’s as of the date of recruitment to this study. Median time since diagnosis for those in 
Drug Naïve group was 0 year whereas those in Medication group was 3 years.  
 
ID Year of diagnosis Group Time since diagnosis 
(years) when 
recruited 
210717_005 2017 Drug Naive 0 
210717_006 2017 Drug Naive 0 
210717_016 2013 Drug Naive 4 
210717_019 2017 Drug Naive 0 
210717_022 2016 Drug Naive 1 
210717_023 2015 Drug Naive 2 
210717_025 2017 Drug Naive 0 
210717_028 2013 Drug Naive 4 
210717_030 2016 Drug Naive 1 
210717_033 2017 Drug Naive 0 
210717_038 2015 Drug Naive 2 
181017_009 2017 Drug Naïve 0 
181017_016 2017 Drug Naive 0 
181017_019 2017 Drug Naive 0 
181017_020 2005 Drug Naive 12 
181017_021 2017 Drug Naive 0 
181017_023 2017 Drug Naive 0 
181017_024 2016 Drug Naive 1 
191017_003 2016 Drug Naive 1 
191017_004 2017 Drug Naive 0 
191017_007 2015 Drug Naive 2 
181017_004 2002 Medication 15 
kNN 78% 61% 57% 42% 
SVM 65% 60% 60% 35% 
Random Forest 66% 61% 54% 38% 
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181017_005 2016 Medication 1 
181017_006 2014 Medication 3 
181017_010 2016 Medication 1 
181017_012 2016 Medication 1 
181017_013 2013 Medication 4 
181017_018 2013 Medication 4 
191017_006 2007 Medication 10 
191017_008 2015 Medication 2 
191017_009 2014 Medication 3 
210717_009 2014 Medication 3 
210717_012 2016 Medication 1 
210717_018 2014 Medication 3 
210717_029 2014 Medication 3 
210717_031 2015 Medication 2 
210717_032 2015 Medication 2 
210717_034 2017 Medication 0 
210717_035 2014 Medication 3 
210717_037 2004 Medication 13 
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Figure S1: ROC plots generated using all nine metabolites that were common between the two 
cohorts (A discovery and B validation) (but not necessarily differential using Student’s t-test or 
expressed in the same direction between cohorts). Each model was built using PLS-DA to rank all 
variables and top two important variables were selected to start with. Then in each subsequent 
model additional variables by rank were added to generate ROC curve. Confidence intervals were 
calculated by Monte Carlo Cross Validation (MCCV) using balanced sub-sampling with multiple 
repeats.  
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Figure S2: Schematic to show qualitatively the results of a series of blind randomised studies 
performed by the Super Smeller to classify and score samples based on their similarity to the ‘PD 
smell’ and their overall intensity of smell, these scores were defined by both oral and physical 
denomination by the Super Smeller. All samples were presented on gauze swabs; purple 
pentagons display a cluster of swabs of multiple combinations of candidate compounds spiked 
onto blank gauze (no sebum), orange circles show gauze swabs containing only human control 
sebum (no compounds), blue squares depict three series of compound combinations based on 
MS analysis spiked on to control sebum and green triangles represent clinical gauze samples 
swabbed from PD patients. 
 
 
 
 
 
 
 
